Citizens JMP healthcare analysts hold an analyst/industry conference call
Don't Miss TipRanks' Half-Year Sale
Take advantage of TipRanks Premium at 50% off! Unlock powerful investing tools, advanced data, and expert analyst insights to help you invest with confidence.
Make smarter investment decisions with TipRanks' Smart Investor Picks, delivered to your inbox every week.
Try Our AI Features
Explore what Daily8 AI can do for you:
Comments
No comments yet...
Related Articles
Yahoo
a day ago
- Yahoo
This Stock Is Up by 800% This Year -- but Is It a Buy?
Key Points Abivax's shares skyrocketed following positive clinical trial results for its lead candidate, obefazimod. This investigational medicine could prove more effective than existing drugs for ulcerative colitis. There might be plenty of upside left if obefazimod produces more positive results in further trials. 10 stocks we like better than Abivax Société Anonyme › If you had invested money in Abivax (NASDAQ: ABVX) at the beginning of the year, you would be sitting pretty right now. The French biotech's shares recently skyrocketed and are up more than 800% year to date. As investors can probably guess, Abivax's gains are tied to impressive clinical progress for its leading pipeline candidate. However, some might worry that it's too late to buy the stock now. Is that the case? Let's look deeper into what's going on with Abivax and determine whether there's any upside left. A potential first-in-class drug Abivax's leading pipeline candidate is called obefazimod, a potential treatment for ulcerative colitis (UC). It could be a first-in-class drug, meaning a medicine that has a novel mechanism of action distinct from those of existing therapies targeting the same condition. First-in-class drugs sometimes prove more effective than standard existing treatments, so there is significant potential for a smaller biotech company working on a medicine like this one, if it can ace clinical trials. Abivax has just achieved exactly that, with strong results from a pair of phase 3 trials for obefazimod. The medicine led to a high rate of remission among participants with moderate to severely active UC, compared to a placebo. Importantly, the studies included patients who had never received any advanced therapy for UC, as well as some who had but had previously failed to achieve remission. According to Abivax, 47.3% of participants in these trials had an inadequate response to prior therapy. In other words, obefazimod succeeded in helping some patients achieve remission where other medicines had failed. And this isn't an obscure therapeutic area with just a couple of options, either: It's actually a highly competitive market. There are numerous advanced therapies for UC, including some produced by several of the world's largest pharmaceutical companies. That makes obefazimod's success all the more impressive. Why it may not be too late to buy the stock Abivax's market capitalization is now 3.7 billion euros (about $4.3 billion). Some analysts estimate that obefazimod could hit peak sales of about $4 billion. Of course, it won't get there anytime soon, even if it earns approval. Though the data looks strong so far, there is more to come. The recent results Abivax shared were from induction trials (to see whether a medicine can reduce the symptoms of a disease). The biotech has an ongoing maintenance study (to check whether it can keep the disease under control), the results of which it plans to share in the second quarter of 2026. If this data isn't up to Wall Street's liking, Abivax's shares might plunge. That's to say nothing of potential regulatory setbacks, which aren't that rare with smaller biotech companies and could also sink the company's stock price. So there are some risks involved, but the stock might be worth it for those who can stomach the volatility. Abivax has developed a medicine with a novel mechanism of action that performs well in clinical trials, and that ability speaks volumes about the company's innovative capabilities. Meanwhile, although funding was an issue at the start of the year, it should no longer be a problem. Abivax ended the first quarter with 103.6 million euros in cash ($120.1 million), which management thought would only last until the end of this year. Thanks to obefazimod's phase 3 results and the company's stock price soaring, Abivax announced a secondary offering, during which it expects to generate gross proceeds of 637.5 million euros ($747.5 million). That should be plenty of money for the company to keep the lights on, even beyond next year. There's still significant upside left if the ongoing phase 3 clinical trials for obefazimod in UC also yield strong results. Additionally, Abivax is testing its lead candidate as a monotherapy for Crohn's disease, as well as a potential combination treatment for UC. Consistent positive clinical and regulatory developments could lead to even more gains for patient investors. That's why it might still be time for those with above-average risk tolerance to initiate a small position in the stock. Should you buy stock in Abivax Société Anonyme right now? Before you buy stock in Abivax Société Anonyme, consider this: The Motley Fool Stock Advisor analyst team just identified what they believe are the for investors to buy now… and Abivax Société Anonyme wasn't one of them. The 10 stocks that made the cut could produce monster returns in the coming years. Consider when Netflix made this list on December 17, 2004... if you invested $1,000 at the time of our recommendation, you'd have $638,629!* Or when Nvidia made this list on April 15, 2005... if you invested $1,000 at the time of our recommendation, you'd have $1,098,838!* Now, it's worth noting Stock Advisor's total average return is 1,049% — a market-crushing outperformance compared to 182% for the S&P 500. Don't miss out on the latest top 10 list, available when you join Stock Advisor. See the 10 stocks » *Stock Advisor returns as of July 29, 2025 Prosper Junior Bakiny has no position in any of the stocks mentioned. The Motley Fool has no position in any of the stocks mentioned. The Motley Fool has a disclosure policy. This Stock Is Up by 800% This Year -- but Is It a Buy? was originally published by The Motley Fool Error in retrieving data Sign in to access your portfolio Error in retrieving data Error in retrieving data Error in retrieving data Error in retrieving data
Business Insider
2 days ago
- Business Insider
IBM and Cleveland Clinic Build an AI Model that Predicts Brain Disorders
The way people walk, their gait, can reveal early signs of serious neurological conditions such as Parkinson's disease, cerebral palsy, dementia, and cognitive decline. Subtle differences in stride, balance, and timing often give clues about these conditions, but traditional gait assessments rely heavily on visual observation by doctors. This approach can be subjective, time‑consuming, and limited to controlled environments. However, a new collaboration between tech giant IBM (IBM) and Cleveland Clinic hopes to change this by creating an AI system that can work with many types of neurological conditions and sensor setups, including everyday devices like smartphone cameras and wearables. Elevate Your Investing Strategy: Take advantage of TipRanks Premium at 50% off! Unlock powerful investing tools, advanced data, and expert analyst insights to help you invest with confidence. At the center of this work is an AI foundation model called GaitFM, trained on a mix of real and synthetic data. Most of the training data comes from physics‑based simulations of walking that mimic the effects of age, disease, and different types of sensors. This synthetic data helps solve a major problem in gait research: there is very little gait data available online. By first training on synthetic data and then fine‑tuning with smaller clinical datasets, GaitFM can recognize the gait patterns of different diseases. Early tests show that GaitFM can estimate key movement features, classify conditions, and even predict disease progression. In studies, models trained on synthetic data alone were able to perform competitively, and combining synthetic with real data provided the best results. The technology is already being piloted at Cleveland Clinic and recently won Best Paper at the 2025 IEEE International Conference on Digital Health. Researchers believe this approach could make gait analysis widely accessible and scalable, especially for rare conditions where collecting real data is difficult. Is IBM a Buy, Sell, or Hold? Turning to Wall Street, analysts have a Moderate Buy consensus rating on IBM stock based on seven Buys, four Holds, and one Sell assigned in the past three months, as indicated by the graphic below. Furthermore, the average IBM price target of $297.33 per share implies 14.5% upside potential.
Business Insider
4 days ago
- Business Insider
Why Is Celcuity Stock (CELC) Up 210% Today?
Celcuity (CELC) stock rocketed higher on Monday after the clinical-stage biotechnology company announced positive topline results from the PIK3CA wild-type cohort of the Phase 3 VIKTORIA-1 clinical trial. This trial is focused on the study of gedatolisib plus fulvestrant with and without palbociclib versus fulvestrant as a treatment for adults with hormone receptor (HR)-positive, human epidermal growth factor receptor 2 (HER2)-negative, PIK3CA wild-type, locally advanced or metastatic breast cancer. Elevate Your Investing Strategy: Take advantage of TipRanks Premium at 50% off! Unlock powerful investing tools, advanced data, and expert analyst insights to help you invest with confidence. The big news here is that the gedatolisib triplet showed statistically significant and clinically meaningful improvement in progression-free survival (PFS), reducing the risk of progression or death by 76% when compared to fulvestrant. The gedatolisib doublet also showed statistically significant and clinically meaningful improvement in PFS, reducing the risk of progression or death by 67% compared to fulvestrant. Sara Hurvitz, co-investigator of the Celcuity clinical trial, said the results were 'potentially practice-changing.' She noted that 'we have not seen Phase 3 results in patients with HR-positive, HER2-negative advanced breast cancer before where there was a quadrupling of the likelihood of survival without disease progression relative to the study control.' Celcuity Stock Movement Today Celcuity stock was up 212.35% during pre-market trading on Monday, following a 1.99% dip on Friday. The company's shares were also up 5.19% year-to-date but down 23.29% over the past 12 months. Today's rally came with heavy trading, as some 5 million shares changed hands, compared to a three-month daily average of about 250,000 units. Is Celcuity Stock a Buy, Sell, or Hold? Turning to Wall Street, the analysts' consensus rating for Celcuity is Strong Buy, based on seven Buy ratings over the past three months. With that comes an average CELC stock price target of $28.25, representing a potential 105.16% upside for the shares.
